HARBIN GLORIA PHARMACEUTICALS Past Earnings Performance
Past criteria checks 2/6
HARBIN GLORIA PHARMACEUTICALS has been growing earnings at an average annual rate of 40.3%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 15.2% per year. HARBIN GLORIA PHARMACEUTICALS's return on equity is 8.7%, and it has net margins of 6%.
Key information
40.3%
Earnings growth rate
40.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -15.2% |
| Return on equity | 8.7% |
| Net Margin | 6.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How HARBIN GLORIA PHARMACEUTICALS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,538 | 153 | 1,190 | 86 |
| 31 Dec 23 | 2,626 | 120 | 1,244 | 85 |
| 30 Sep 23 | 2,745 | -98 | 1,154 | 87 |
| 30 Jun 23 | 2,941 | -290 | 1,302 | 101 |
| 31 Mar 23 | 3,015 | -272 | 1,329 | 95 |
| 01 Jan 23 | 3,108 | -291 | 1,518 | 101 |
| 30 Sep 22 | 3,242 | -35 | 2,157 | 114 |
| 30 Jun 22 | 3,207 | -43 | 2,094 | 92 |
| 31 Mar 22 | 3,214 | 24 | 2,094 | 91 |
| 01 Jan 22 | 3,145 | 45 | 2,058 | 98 |
| 30 Sep 21 | 3,159 | -147 | 2,213 | 119 |
| 30 Jun 21 | 3,187 | -154 | 2,260 | 132 |
| 31 Mar 21 | 3,179 | -237 | 2,264 | 136 |
| 31 Dec 20 | 3,055 | 400 | 2,185 | 125 |
| 30 Sep 20 | 3,291 | -2,314 | 2,195 | 172 |
| 30 Jun 20 | 3,725 | -2,225 | 2,344 | 177 |
| 31 Mar 20 | 4,376 | -2,089 | 2,659 | 183 |
| 31 Dec 19 | 5,054 | -2,662 | 3,043 | 186 |
| 30 Sep 19 | 5,496 | 122 | 3,385 | 119 |
| 30 Jun 19 | 5,678 | 132 | 3,562 | 107 |
| 31 Mar 19 | 5,541 | 113 | 3,447 | 115 |
| 31 Dec 18 | 5,481 | 126 | 3,365 | 122 |
| 30 Sep 18 | 5,015 | 337 | 3,023 | 119 |
| 30 Jun 18 | 4,314 | 316 | 2,498 | 138 |
| 31 Mar 18 | 3,641 | 287 | 2,001 | 105 |
| 31 Dec 17 | 3,042 | 310 | 1,477 | 80 |
| 30 Sep 17 | 2,882 | 434 | 1,014 | 42 |
| 30 Jun 17 | 2,892 | 582 | 851 | 0 |
| 31 Mar 17 | 2,967 | 673 | 761 | 0 |
| 31 Dec 16 | 2,984 | 717 | 770 | 0 |
| 30 Sep 16 | 2,845 | 736 | 744 | 0 |
| 30 Jun 16 | 2,773 | 695 | 754 | 0 |
| 31 Mar 16 | 2,770 | 704 | 785 | 0 |
| 31 Dec 15 | 2,681 | 665 | 780 | 0 |
| 30 Sep 15 | 2,462 | 645 | 714 | 0 |
| 30 Jun 15 | 2,264 | 565 | 704 | 0 |
| 31 Mar 15 | 2,128 | 502 | 705 | 0 |
| 31 Dec 14 | 1,906 | 444 | 654 | 0 |
| 30 Sep 14 | 1,730 | 390 | 680 | 0 |
| 30 Jun 14 | 1,597 | 337 | 708 | 0 |
| 31 Mar 14 | 1,405 | 274 | 801 | 0 |
| 31 Dec 13 | 1,308 | 227 | 801 | 0 |
| 30 Sep 13 | 1,199 | 201 | 714 | 0 |
| 30 Jun 13 | 996 | 180 | 554 | 0 |
Quality Earnings: 002437 has a large one-off gain of CN¥84.1M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002437 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002437's earnings have grown significantly by 40.3% per year over the past 5 years.
Accelerating Growth: 002437 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 002437 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 002437's Return on Equity (8.7%) is considered low.